Skip to content

Twist Bioscience

US · TWST #1258 by market cap Listed 2018
155.65 -11.32 -6.78%
Live - 5344 symbols - heartbeat 50s ago · 2026-10-08 06:50
Pre-market 151.80 -2.47%
After-hours 155.50 -0.10%
Overnight 154.61 -0.67%
Market cap
10.32B
P/B
23.15
EPS
-1.30
Reader sentiment Are you bullish or bearish on TWST?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 29.24 Expensive vs history 100th percentile
5-year average 4.87 · #493 of 514 in Biotechnology
P/E ratio -88.24 Cheap vs history 0th percentile
5-year average -18.13 · forward -132.07
P/S ratio 30.18 Expensive vs history 95th percentile
5-year average 10.61 · forward 24.97 · #226 of 388 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Twist Bioscience (TWST) 10.32B -69.80 23.15 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value158.36 Economic moatNone UncertaintyHigh

Trading 1.7% below Morningstar's fair value estimate.

Fair value

Twist Bioscience Corp receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 22% premium over our quantitative fair value estimate of $158.36 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's lack of profitability weakens our quantitative valuation. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of -0.7%, which ranks in the bottom 30% compared with global peers. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are expensive.

The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to revenue ratio of 27.9, for example, falls in the top 10% globally. This overstates the long-term cash flow growth potential of the organization. This characteristic further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 06:50:15 · For reference only, not investment advice and not tailored to your situation.